News articles about BioSpecifics Technologies Corp (NASDAQ:BSTC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioSpecifics Technologies Corp earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.6641859292554 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of BioSpecifics Technologies Corp (BSTC) traded down 0.44% on Friday, reaching $47.80. 18,334 shares of the company were exchanged. The firm has a market capitalization of $342.44 million, a PE ratio of 29.33 and a beta of 1.76. The company’s 50 day moving average is $46.88 and its 200 day moving average is $51.02. BioSpecifics Technologies Corp has a 12-month low of $38.89 and a 12-month high of $58.79.
BSTC has been the topic of several recent research reports. Zacks Investment Research upgraded shares of BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, HC Wainwright set a $72.00 price objective on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a research note on Thursday, August 10th.
BioSpecifics Technologies Corp Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with our FREE daily email newsletter.